Status:
COMPLETED
The Use of International GerdQ Questionnaire
Lead Sponsor:
AstraZeneca
Conditions:
Gastroesophageal Reflux Disease
Eligibility:
All Genders
18+ years
Brief Summary
There are three main directions for use GerdQ in practice. First of all, GerdQ can be used to diagnose GERD with an accuracy comparable to the accuracy of diagnosis of GERD by the specialist (gastroen...
Detailed Description
Observational non-interventional study on the use of international GerdQ questionnaire for the diagnosis of gastroesophageal reflux disease in the Russian practice
Eligibility Criteria
Inclusion
- Signing of informed consent to participate in the study
- patients of both sexes, 18 years and older
- planned esophagogastroduodenoscopy
Exclusion
- Surgical intervention for upper digestive tract (surgery for gastroesophageal reflux disease, peptic ulcer disease, etc.) In the past
- the presence of contraindications for esophagogastroduodenoscopy or pH-metry
- refusal to sign informed consent
- acceptance of antisecretory drugs (proton pump inhibitors, h2-receptor blockers), antacids and prokinetics for 7 days before enrollment
- Pregnancy
- Confirmed or suspected malignancy
- Impairment of the mental sphere
- Acceptance of nsaids (including acetylsalicylic acid at a dose of 150 mg / day), cytostatics, antibiotics (tetracyclines, lincosamides) at enrollment and during the preceding 30 days
Key Trial Info
Start Date :
February 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT01489735
Start Date
February 1 2012
End Date
June 1 2012
Last Update
January 28 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research site
Moscow, Russia